Xcout Intel
A2 Biotherapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to A2 Biotherapeutics, Inc. among biotechnology companies — ranked by similarity to what A2 Biotherapeutics, Inc. actually does, not by market-cap band.
Subscribe to see A2 Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
A2 Biotherapeutics, Inc. at a glance
A2 Biotherapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $223.1M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $80M in January 2025. Xcout tracks 10 named people at A2 Biotherapeutics, Inc., including James Robinson (President & Chief Executive Officer).
A2 Biotherapeutics, Inc. leadership
- James RobinsonPresident & Chief Executive Officer
- Jim Robinsonchief executive officer
- Agi Hamburger, Ph.D.Chief Operating Officer
- Thomas LeungChief Financial Officer
- John Welch, M.D., Ph.D.Chief Medical Officer
- Vikram JoshiChief Business Officer
4 more named people on record for A2 Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
A2 Biotherapeutics, Inc. funding rounds
At least $223.1M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $80M | 2 named | |
| SEC Form D filing | $71.6M | — | |
| SEC Form D filing | $71.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 A2 Biotherapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to A2 Biotherapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Biotech
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Biotech
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Biotech
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Similar biotechnology company
Aro Biotherapeutics is a U.S. biotechnology company developing targeted therapeutics using its Centyrin protein platform, including delivery of genetic medicines to specific tissues and cells. It serves patients with serious diseases and partners or works with biopharmaceutical organizations to advance targeted drug-development programs.
Similar biotechnology company
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company headquartered in Morristown, New Jersey, focused on developing precision therapies for genetically defined cancers.
Biotech
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Similar biotechnology company
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Similar biotechnology company
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Biotech
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of A2 Biotherapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for A2 Biotherapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →